Ethical and medical considerations of androgen deprivation treatment of sex offenders

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 12, 2011, Pages 3628-3637

  Gooren, Louis J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; GONADORELIN AGONIST; LEUPRORELIN; MEDROXYPROGESTERONE; PLACEBO; TESTOSTERONE; TRIPTORELIN;

ADRENAL SUPPRESSION; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; ATHEROSCLEROSIS; BLOOD PRESSURE; BONE DENSITY; BREAST TENDERNESS; CANCER PATIENT; CHOLELITHIASIS; DEPRESSION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HAIR GROWTH; HEART DEATH; HEART INFARCTION; HOT FLUSH; HUMAN; HUMAN RIGHTS; INFORMED CONSENT; ISCHEMIC HEART DISEASE; MALAISE; MALE INFERTILITY; MEDICAL ETHICS; META ANALYSIS (TOPIC); METABOLIC DISORDER; MIGRAINE; MOOD DISORDER; MUSCLE CRAMP; PATIENT MONITORING; PHLEBITIS; PRIORITY JOURNAL; PROSTATE CANCER; RECIDIVISM; REVIEW; RISK ASSESSMENT; SEXUAL BEHAVIOR; SEXUAL CRIME; SEXUAL DEVIATION; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VERTIGO; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; FRACTURE; MALE; MORALITY; OFFENDER;

ANDROGEN ANTAGONISTS; CRIMINALS; FRACTURES, BONE; HUMAN RIGHTS; HUMANS; MALE; MORALS; SEX OFFENSES;

EID: 83155175582     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1540     Document Type: Review

References (120)

1. Bancroft J 2009 Human sexuality and its problems. 3rd ed. NewYork: Churchill Livingstone
2. Pfaus JG 2009 Pathways of sexual desire. J Sex Med 6:1506-1533
3. Berlin FS 2008 Basic science and neurobiological research: potential relevance to sexual compulsivity. Psychiatr Clin North Am 31:623-642
4. Codispoti VL 2008 Pharmacology of sexually compulsive behavior. Psychiatr Clin North Am 31:671-679
5. Schober JM, Pfaff D 2007 The neurophysiology of sexual arousal. Best Pract Res Clin Endocrinol Metab 21:445-461 (Pubitemid 47387102)
6. Laws DR, O'Donohue WT 2008 Sexual deviance. Theory, assessment, and treatment. New York: Guilford Press
7. 2000 Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th ed. Washington DC: American Psychiatric Association
8. Fazel S, Sjöstedt G, Grann M, Långström N 2010 Sexual offending in women and psychiatric disorder: a national case-control study. Arch Sex Behav 39:161-167
9. Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, Schulman C, Tan HM, Torres LO, Yassin A, Zitzmann M 2010 Endocrine aspects of male sexual dysfunctions. J Sex Med 7:1627-1656
10. Bancroft J 2005 The endocrinology of sexual arousal. J Endocrinol 186:411-427 (Pubitemid 41404061)
11. Jordan K, Fromberger P, Stolpman G, Muller JL 2 August 2011 The role of testosterone in sexuality and paraphilia-A neurobiological approach. Part I: Testosterone and sexuality. J Sex Med 10.1111/j.1743-6109.2011.02394.x
12. Guay DR 2009 Drug treatment of paraphilic and nonparaphilic sexual disorders. Clin Ther 31:1-31
13. Fedoroff JP 2009 The paraphilias. In: Gelder MG, ed. New Oxford textbook of psychiatry. 2nd ed. Oxford, UK: Oxford University Press; 832-842
14. Schmucker M, Lösel F 2008 Does sexual offender treatment work? Asystematic review of outcome evaluations. Psicothema 20:10-19
15. Hanson RK, Bourgon G, Helmus L, Hodgson S 2009 The principles of effective correctional treatment also apply to sexual offenders. A meta-analysis. Crim Justice Behav 36:865-891
16. Thibaut F, De La Barra F, Gordon H, Cosyns P, Bradford JM 2010 The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World J Biol Psychiatry 11:604-655
17. Ward T, Gannon TA 2006 Rehabilitation, etiology, and self-regulation: the comprehensive good lives model of treatment for sexual offenders. Aggress Violent Behav 11:77-94 (Pubitemid 41815598)
18. Stinson JD, Sales BD, Becker JV 2008 Sex offending. Causal theories to inform research, prevention, and treatment. American Psychological Association. Washington DC: SAGE Publications
19. Saleh FM, Malin HM, Grudzinskas Jr AJ, Vitacco MJ 2010 Paraphilias with co-morbid psychopathy: the clinical and legal significance to sex offender assessments. Behav Sci Law 28:211-223
20. Ward T, Birgden A 2007 Human rights and correctional clinical practice. Aggress Violent Behav 12:628-643 (Pubitemid 47562829)
21. Marshall WL, Marshall LE, Serran GE, O'Brien MD 2011 Rehabilitating sexual offenders. A strength-based approach. Washington DC: American Psychological Association
22. Gijs L, Gooren, L 1996 Hormonal and psychopharmacological interventions in the treatment of paraphilias: an update. J Sex Res 33:273-290 (Pubitemid 26424989)
23. Krueger RB, Wexler R, Kaplan M, Saleh F 2009 Orchiectomy. In: Saleh FM, Bradford JM, Grudzinsakas AJ, Brodsky DJ, eds. Sex offenders. New York: Oxford University Press; 171-188
24. Losel F, Schmucker M 2005 The effectiveness of treatment for sexual offenders: a comprehensive meta-analysis. J Exp Criminol 1:1-29
25. Jordan K, Fromberger P, Stolpman G, Müller JL 28 July 2011 The role of testosterone in sexuality and paraphilia-A neurobiological approach. Part II: Testosterone and paraphilia. J Sex Med 10.1111/j.1743-6109.2011.02393.x
26. Prentky RA 1997 Arousal reduction in sexual offenders: a review of antiandrogen interventions. Sex Abuse 9:335-347
27. Maletzky BM, Tolan A, McFarland B 2006 The Oregon depo-Provera program: a five-year follow-up. Sex Abuse 18:303-316 (Pubitemid 44451418)
28. Grubin D 2008 Medical models and interventions in sexual deviance. In: Laws DR, O'Donohue WT, eds. Sexual deviance: theory, assessment, and treatment. 2nd ed. New York: Guildford Press; 594-610
29. Grubin D, Beech A 2010 Chemical castration for sex offenders. BMJ 340:c74
30. Smith CM 2005 Origin and uses of primum non nocere - above all, do no harm! J Clin Pharmacol 45:371-377 (Pubitemid 40490410)
31. Birgden A, Perlin ML 2009 "Where the home in the valley meets the damp dirty prison": A human rights perspective on therapeutic jurisprudence and the role of forensic psychologists in correctional settings. Aggress Violent Behav 14:256-263
32. Ward T, Gannon TA, Birgden A 2007 Human rights and the treatment of sex offenders. Sex Abuse 19:195-216
33. Saleh FM, Grudzinskas Jr AJ, Malin HM, Dwyer RG 2010 The management of sex offenders: perspectives for psychiatry. Harv Rev Psychiatry 18:359-368
34. Mann RE, Hanson RK, Thornton D 2010 Assessing risk for sexual recidivism: some proposals on the nature of psychologically meaningful risk factors. Sex Abuse 22:191-217
35. Andrews DA, Bonta J 2010 The psychology of criminal conduct. 5th ed. New Providence, NJ: LexisNexis Matthew Bender
36. Bradford JM, Federoff P 2008 Pharmacological treatment of the juvenile sex offender. In: Barbaree HE, Marshall WL, eds. The juvenile sex offender. New York: Guilford Press; 358-395
37. Seto MC, Lalumière ML 2010 What is so special about male adolescent sexual offending? A review and test of explanations through meta-analysis. Psychol Bull 136:526-575
38. Sawyer AM, Borduin CM 25 July 2011 Effects of multisystemic therapy through midlife: a 21.9-year follow-up to a randomized clinical trial with serious and violent juvenile offenders. J Consult Clin Psychol 10.1037/a0024862
39. Dwyer RG, Letourneau EJ 2011 Juveniles who sexually offend: recommending a treatment program and level of care. Child Adolesc Psychiatr Clin N Am 20:413-429
40. Delemarre-van de Waal HA, Cohen-Kettenis PT 2006 Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. Eur J Endocrinol 155:S131-S137 (Pubitemid 44902271)
41. Sajith SG, Morgan C, Clarke D 2008 Pharmacological management of inappropriate sexual behaviours: a review of its evidence, rationale and scope in relation to men with intellectual disabilities. J Intellect Disabil Res 52:1078-1090
42. Birgden A, Cucolo H 2011 The treatment of sex offenders: evidence, ethics, and human rights. Sex Abuse 23:295-313
43. Giltay EJ, Gooren LJ 2009 Potential side effects of androgen deprivation treatment in sex offenders. J Am Acad Psychiatry Law 37:53-58
44. Harrison K, Rainey B 2011 Morality and legality in the use of anti-androgenic pharmacotherapy with sex offenders. In: Boer D, et al., eds. International perspectives on the assessment and treatment of sexual offenders theory, practice and research. Chichester, UK: Wiley-Blackwell; 627-654
45. Jones N, Pelissier B, Klein-Saffran J 2006 Predicting sex offender treatment entry among individuals convicted of sexual offense crimes. Sex Abuse 18:83-98 (Pubitemid 44065566)
46. Perachino M, Cavalli V, Bravi F 2010 Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 105:648-651
47. Schober JM, Kuhn PJ, Kovacs PG, Earle JH, Byrne PM, Fries RA 2005 Leuprolide acetate suppresses pedophilic urges and arousability. Arch Sex Behav 34:691-705 (Pubitemid 41803666)
48. Schober JM, Byrne PM, Kuhn PJ 2006 Leuprolide acetate is a familiar drug that may modify sex-offender behaviour: the urologist's role. BJU Int 97:684-686
49. Briken P, Kafka MP 2007 Pharmacological treatments for paraphilic patients and sexual offenders. Curr Opin Psychiatry 20:609-613
50. Krueger RB, Kaplan MS 2002 Behavioral and psychopharmacological treatment of the paraphilic and hypersexual disorders. J Psychiatr Pract 8:21-32
51. Gooren LJ 1987 Androgen levels and sex functions in testosterone-treated hypogonadal men. Arch Sex Behav 16:463-473
52. Kelleher S, Conway AJ, Handelsman DJ 2004 Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 89:3813-3817 (Pubitemid 39071477)
53. Zitzmann M, Faber S, Nieschlag E 2006 Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 91:4335-4343 (Pubitemid 44833407)
54. Bagatell CJ, Heiman JR, Rivier JE, Bremner WJ 1994 Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J Clin Endocrinol Metab 78:711-716 (Pubitemid 24083316)
55. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW 2001 Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281:E1172-E1181
56. Neumann F, Kalmus J 1991 Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience. Exp Clin Endocrinol 98:71-80
57. Cremoncini C, Vignati E, Libroia A 1976 Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinylestradiol. Acta Eur Fertil 7:299-314 (Pubitemid 8064900)
58. Heinemann LA, Will-Shahab L, van Kesteren P, Gooren LJ 1997 Safety of cyproterone acetate: report of active surveillance. Pharmacoepidemiol Drug Saf 6:169-178 (Pubitemid 27304251)
59. Bradford JM, Pawlak A 1993 Double-blind placebo crossover study of cyproterone acetate in the treatment of the paraphilias. Arch Sex Behav 22:383-402 (Pubitemid 23308999)
60. Bradford JM 2000 The treatment of sexual deviation taking a pharmacological approach. J Sex Res 37:248-257
61. Appelt M, Floru L 1974 [The effect on sexuality of cyproterone acetate]. Int Pharmacopsychiatry 9:61-76
62. Grossman LS, Martis B, Fichtner CG 1999 Are sex offenders treatable? A research overview. Psychiatr Serv 50:349-361 (Pubitemid 29122563)
63. Hucker S, Langevin R, Bain J 1988Adouble-blind trial of sex drive lowering medication in pedophiles. Ann Sex Res 1:227-242
64. Krueger RB, Kaplan MS 2001 Depot-leuprolide acetate for treatment of paraphilias: a report of twelve cases. Arch Sex Behav 30:409-422 (Pubitemid 39592019)
65. Rösler A, Witztum E 2000 Pharmacotherapy of paraphilias in the next millennium. Behav Sci Law 18:43-56 (Pubitemid 30206753)
66. Briken P, Hill A, Berner W 2003 Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review. J Clin Psychiatry 64:890-897 (Pubitemid 37022754)
67. Rösler A, Witztum E 1998 Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med 338:416-422 (Pubitemid 28135668)
68. Rochira V, Granata AR, Madeo B, Zirilli L, Rossi G, Carani C 2005 Estrogens in males: what have we learned in the last 10 years? Asian J Androl 7:3-20 (Pubitemid 40361061)
69. Khosla S 2010 Update on estrogens and the skeleton. J Clin Endocrinol Metab 95:3569-3577
70. Dumitriu D, Rapp PR, McEwen BS, Morrison JH 2010 Estrogen and the aging brain: an elixir for the weary cortical network. Ann NY Acad Sci 1204:104-112
71. Luczak ED, Leinwand LA 2009 Sex-based cardiac physiology. Annu Rev Physiol 71:1-18
72. Smith MR 2002 Osteoporosis during androgen deprivation therapy for prostate cancer. Urology 60:79-85; discussion 86
73. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM 2005 Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410-6417 (Pubitemid 41759293)
74. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS 2005 Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164 (Pubitemid 40096612)
75. Hamilton EJ, Ghasem-Zadeh A, Gianatti E, Lim-Joon D, Bolton D, Zebaze R, Seeman E, Zajac JD, Grossmann M 2010 Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab 95:E456-E463
76. Araujo AB, Travison TG, Leder BZ, McKinlay JB 2008 Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J Clin Endocrinol Metab 93:2135-2141 (Pubitemid 351831527)
77. Rucker D, Ezzat S, Diamandi A, Khosravi J, Hanley DA 2004 IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men. Clin Endocrinol (Oxf) 60:491-499
78. Taylor LG, Canfield SE, Du XL 2009 Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115:2388-2399
79. Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L 2010 Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 184:918-923
80. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR 2010 Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 183:2200-2205
81. Ito K, Elkin EB, Girotra M, Morris MJ 2010 Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152:621-629
82. Saad F, Abrahamsson PA, Miller K 2009 Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU Int 104:1573-1579
83. Campbell SC, Bhoopalam N, Moritz TE, Pandya M, Iyer P, Vanveldhuizen P, Ellis NK, Thottapurathu L, Garewal H, Warren SR, Friedman N, Reda DJ 2010 The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology 75:1138-1143
84. Vandenput L, Ohlsson C 2010 Sex steroid metabolism in the regulation of bone health in men. J Steroid Biochem Mol Biol 121:582-588
85. Wadhwa VK, Weston R, Parr NJ 2011 Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer. BJU Int 107:1923-1929
86. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS 2010 Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 184:1316-1321
87. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C 2009 Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745-755
88. Muir VJ, Scott LJ 2010 Denosumab: in cancer treatment-induced bone loss. BioDrugs 24:379-386
89. Shahani S, Braga-Basaria M, Basaria S 2008 Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 93:2042-2049 (Pubitemid 351831513)
90. Basaria S 2008 Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl 29:534-539
91. Haseen F, Murray LJ, Cardwell CR, O'Sullivan JM, Cantwell MM 2010 The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and metaanalysis. J Cancer Surviv 4:128-139
92. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K 2005 The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 90:657-660 (Pubitemid 40279176)
93. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N 2010 Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 60:194-201
94. Smith MR, Lee H, Nathan DM 2006 Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91:1305-1308
95. Galvão DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R 2008 Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 102:44-47
96. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, Zajac JD, Grossmann M 2011 Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 74: 377-383
97. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ 1998 Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 83:1886-1892 (Pubitemid 28496311)
98. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB 2000 Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 23:490-494 (Pubitemid 30185792)
99. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT 2004 Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27: 1036-1041 (Pubitemid 38579762)
100. Li C, Ford ES, Li B, Giles WH, Liu S 2010 Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care 33:1618-1624
101. Smith MR, Malkowicz SB, Chu F, Forrest J, Sieber P, Barnette KG, Rodriquez D, Steiner MS 2008 Toremifene improves lipid profiles inmenreceiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 26: 1824-1829
102. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet 364:685-696 (Pubitemid 39140624)
103. Haseen F, Murray LJ, O'Neill RF, O'Sullivan JM, Cantwell MM 2010 A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy. Trials 11:86
104. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C 2006 Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 367: 1412-1420
105. Seidman SN 2006 Normative hypogonadism and depression: Does 'andropause' exist? Int J Impot Res 18:415-422 (Pubitemid 44330290)
106. Cherrier MM, Aubin S, Higano CS 2009 Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology 18: 237-247
107. Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U 2006 Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 98:20-27 (Pubitemid 43890697)
108. Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW 2010 Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. J Sex Med 7:2996-3010
109. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS 2006 Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 166:465-471
110. Schmidt PJ, Berlin KL, Danaceau MA, Neeren A, Haq NA, Roca CA, Rubinow DR 2004 The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch Gen Psychiatry 61: 997-1004 (Pubitemid 39336533)
111. Sharifi N, Gulley JL, Dahut WL 2005 Androgen deprivation therapy for prostate cancer. JAMA 294:238-244 (Pubitemid 41043794)
112. Timilshina N, Hussain S, Breunis H, Alibhai SM 16 October 2010 Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study. Support Care Cancer 10.1007/s00520-010-1023-6
113. Choo R, Chander S, Danjoux C, Morton G, Pearce A, Deboer G, Szumacher E, Loblaw A, Cheung P, Woo T 2005 How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients? Can J Urol 12:2547-2552
114. Giltay EJ, Gooren LJ 2000 Effects of sex steroid deprivation/ administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 85:2913-2921 (Pubitemid 32269173)
115. Meyer 3rd WJ, Cole C, Emory E 1992 Depo provera treatment for sex offending behavior: an evaluation of outcome. Bull Am Acad Psychiatry Law 20:249-259
116. Bradford JM 2001 The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour. Can J Psychiatry 46:26-34 (Pubitemid 32209342)
117. Berlin FS 2009 Risk/benefit ratio of androgen deprivation treatment for sex offenders. J Am Acad Psychiatry Law 37:59-62
118. Grossmann M, Zajac JD 2011 Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf) 74:289-293
119. Shore ND, Crawford ED 2010 Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol 12:1-11
120. Bhasin S, Jasuja R 2009 Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 12:232-240